

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

NCT07096193

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Gilead Sciences
Enrollment	107 participants

Key Eligibility Criteria

Inclusion (10)

- Part A:
 - Participants assigned male or female at birth who are of childbearing potential and engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
 - Have a body mass index (BMI) of ≥ 30.0 kg/m² at screening and at admission.
 - Part B:
 - Participants assigned male or female at birth who are of childbearing potential and engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
- ... and 5 more (see full listing online)

Exclusion (8)

- Part A:
 - Positive serum or urine pregnancy test.
 - Participants with plans to breastfeed during the study period.
 - Part B:
 - Positive serum or urine pregnancy test.
- ... and 3 more (see full listing online)

Locations (12 total)

Investigative Site, Anaheim, California, United States
University of Maryland, Institute of Human Virology, Clinical Research Unit, Baltimore, Maryland, United States
The New York-Presbyterian Hospital, New York, New York, United States
... and 9 more locations